Redx Pharma to Showcase Cancer Drug at Prestigious Munich Conference

Newsfeed Image, Light Gray Text On Dark Gray Background
Drug developer Redx Pharma Plc is to present a pre-clinical profile of its exciting new Porcupine inhibitor at a cancer conference in Munich later today.

Drugs like Redx’s RXC004 work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Read more . . .